This article walks through five findings the research community is coming back to after May 2026. It is not a clinical guide and does not recommend retatrutide for medical use. Retatrutide as supplied by NorexBio is research-grade peptide intended for in vitro laboratory and analytical research.
For Swedish buyers, the pipeline signal is still practical: once a molecule moves from phase 2 interest into a full phase 3 programme, supplier documentation, stock status, EU dispatch and batch traceability matter more. Start with Retatrutide Sweden when comparing formats, portal pricing and delivery before reading the technical trial details.
1. TRIUMPH-1: 28.3% body-weight reduction at 80 weeks in 2,339 adults
Eli Lilly topline, 21 May 2026. TRIUMPH-1 randomised 2,339 adults with obesity or overweight and at least one weight-related comorbidity (hypertension, dyslipidaemia, sleep apnoea or osteoarthritis) but without diabetes, 1:1:1:1 to placebo, retatrutide 4 mg, 9 mg or 12 mg, delivered as a once-weekly subcutaneous injection. The primary endpoint was percentage weight change at 80 weeks. The 12 mg arm reported a mean reduction of 28.3%.
The headline number came from an extension analysis: participants with a starting BMI of 35 or higher who continued on therapy reached up to 30.3% weight reduction at 104 weeks — approximately 85 lbs (38 kg) on average. Those are the largest weight-loss numbers ever documented for a GLP-1-class agonist in a published phase 3 readout.
2. TRIUMPH-4: knee-osteoarthritis pain relief on top of weight loss
TRIUMPH-4, topline May 2026. The parallel phase 3 trial enrolled adults with obesity and symptomatic knee osteoarthritis. In addition to clinically meaningful weight loss, the trial reported significant pain relief on the validated WOMAC scale versus placebo. It is the first pivotal osteoarthritis finding for a GLP-1-class agonist and strengthens the hypothesis that metabolic therapy can deliver inflammatory and musculoskeletal secondary benefits.
For research context, this matters because it broadens the mechanistic conversation: triple agonism is not only about weight reduction but about a wider metabolic and inflammatory signalling profile. TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) read out later in the year and will fill in the picture further.
3. Phase 2 obesity was the prologue: 24.2% at 48 weeks (NEJM 2023)
Jastreboff et al., New England Journal of Medicine, 2023.The 48-week phase 2 trial in 338 adults with obesity reported a 24.2% reduction on the 12 mg arm, and that result is what motivated the entire TRIUMPH programme. Phase 3 has now not only replicated but exceeded that figure in a substantially larger and longer trial — an unusually well-behaved development track for a GLP-1-class molecule.
The parallel phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) added an HbA1c reduction of up to 2.16 percentage points on the 12 mg dose. That dual signal — weight reduction and glucose homeostasis in the same cohort — is the mechanistically broader finding that pushed phase 3 beyond pure obesity indications.
4. Triple agonism structurally characterised (Cell Metabolism 2022)
Coskun et al., Cell Metabolism, 2022. The characterisation paper for LY3437943 (retatrutide as a molecule) confirmed simultaneous activation of three receptors: the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
This is the structural addition that distinguishes retatrutide from tirzepatide: tirzepatide activates GLP-1R and GIPR, retatrutide adds GCGR activation, which engages hepatic glucose output and energy expenditure. The preclinical pharmacology is the reason the molecule moved from preclinic to phase 3 as quickly as it did.
5. The TRIUMPH programme at scale: 8 trials, 5,800+ participants
| Trial | Population | Status |
|---|---|---|
| TRIUMPH-1 | Obesity without diabetes | Topline reported (May 2026) |
| TRIUMPH-4 | Obesity + knee osteoarthritis | Topline reported (May 2026) |
| TRIUMPH-2 | Obesity + type 2 diabetes | Expected to read out 2026 |
| TRIUMPH-3 | Obesity + established CV disease | Expected to read out 2026 |
| CV outcomes trial | ~10,000 participants | Separate long-term study |
8 pivotal phase 3 trials, over 5,800 participants in obesity and diabetes indications.
Eli Lilly's TRIUMPH programme is one of the most ambitious phase 3 packages in the metabolic field: eight pivotal trials, over 5,800 participants in obesity and diabetes indications combined, plus a separate cardiovascular outcomes trial at roughly 10,000 participants. TRIUMPH-1 and TRIUMPH-4 have reported; TRIUMPH-2 (T2D) and TRIUMPH-3 (established CV disease) read out later in 2026.
The programme's breadth is the fifth finding in its own right: regulators review programme totality, not single trials, and retatrutide has assembled one of the most complete phase 3 packages in its class. Until that package is reviewed in full, the molecule remains an investigational compound, and retatrutide as supplied by NorexBio remains research material for in vitro laboratory use.
Summary
Full primary literature and DOI links live on our science page, and handling and quality specifications for the research pens are on the quality page. For buyer-facing context, continue to Retatrutide Sweden.